Summary:

- The article discusses the successful completion of the PATH trial, the first large-scale randomized clinical trial for Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder.
- The trial was sponsored by the National Institutes of Health (NIH) and involved the collaboration of the Cure HHT advocacy organization, which helped raise awareness and support for the study.
- The successful trial results are a significant milestone in the development of treatments for HHT, a condition that can lead to life-threatening complications, and the article highlights the importance of patient advocacy in advancing rare disease research.